How should I evaluate and manage a patient with a heart rate of 117 beats per minute?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evaluation and Management of Heart Rate 117 bpm

A heart rate of 117 bpm requires immediate assessment of hemodynamic stability and identification of the underlying cause—this is most commonly physiologic sinus tachycardia responding to a stressor (fever, anemia, dehydration, hypoxia, pain, anxiety) rather than a primary arrhythmia, and treating the underlying cause is the priority. 1

Initial Assessment

Determine hemodynamic stability first:

  • Assess for signs of shock, altered mental status, chest pain, acute heart failure, or hypotension attributable to the tachycardia 1
  • If the patient is unstable with these findings, proceed immediately to synchronized cardioversion 1
  • If stable, proceed with systematic evaluation 1

Obtain diagnostic workup without delaying treatment if unstable:

  • Attach cardiac monitor and establish IV access 1
  • Obtain 12-lead ECG to define the rhythm (narrow vs. wide complex) 1
  • Evaluate blood pressure and pulse oximetry 1
  • Provide supplementary oxygen if signs of increased work of breathing or inadequate oxygenation are present 1

Identify the Rhythm and Underlying Cause

The most critical step is distinguishing sinus tachycardia from a primary arrhythmia:

Sinus Tachycardia (Most Common at HR 117)

  • Do not treat the heart rate directly—sinus tachycardia is physiologic and requires identification and treatment of the underlying cause 1
  • The upper limit of sinus tachycardia is approximately 220 minus the patient's age 1
  • Common reversible causes include: fever, anemia, hypotension, dehydration, hypoxia, pain, anxiety, pulmonary embolism, sepsis 1
  • Critical warning: When cardiac function is poor, cardiac output depends on rapid heart rate, and "normalizing" the rate can be detrimental 1

Supraventricular Tachycardia (SVT)

  • Typically presents with heart rate 150-250 bpm, regular rhythm, narrow QRS complex 2
  • P waves usually hidden within QRS complex 2
  • Abrupt onset of palpitations, dizziness, dyspnea, or chest pain 2
  • At HR 117, SVT is less likely unless the patient is on rate-controlling medications 3, 4

Atrial Fibrillation with Rapid Ventricular Response

  • Irregularly irregular rhythm distinguishes this from sinus tachycardia 1
  • Target resting heart rate <100-110 bpm for adequate rate control 5, 6
  • The European Society of Cardiology recommends lenient rate control (<110 bpm at rest) for most patients 5

Management Based on Clinical Context

If Sinus Tachycardia (Most Likely)

Treat the underlying cause, not the heart rate:

  • Correct fever with antipyretics 1
  • Treat dehydration with IV fluids 1
  • Address hypoxia with supplementary oxygen 1
  • Manage pain appropriately 1
  • Treat anemia if present 1
  • Rule out and treat sepsis, pulmonary embolism, or other acute conditions 1

If Atrial Fibrillation with RVR

For hemodynamically stable patients:

  • Beta-blockers (metoprolol 2.5-5.0 mg IV every 2-5 minutes) or non-dihydropyridine calcium channel blockers (diltiazem 20 mg IV over 2 minutes) are first-line for rate control 1
  • Target resting heart rate <110 bpm (lenient control) for most patients 5
  • Stricter control (<80 bpm) reserved for symptomatic patients or suspicion of tachycardia-induced cardiomyopathy 5
  • Avoid diltiazem and verapamil in patients with heart failure with reduced ejection fraction 7, 5

If SVT (Less Likely at HR 117)

For hemodynamically stable patients:

  • Attempt vagal maneuvers first (Valsalva maneuver, carotid massage) unless this will unduly delay treatment 1
  • Adenosine 6 mg rapid IV push followed by NS flush; if no response, give 12 mg 1
  • Adenosine terminates approximately 95% of AVNRT cases 1

Critical Pitfalls to Avoid

Never use AV nodal blocking agents in Wolff-Parkinson-White syndrome with wide-complex tachycardia:

  • Beta-blockers, calcium channel blockers, digoxin, and adenosine can accelerate ventricular rate and precipitate ventricular fibrillation 1

Do not aggressively treat compensatory tachycardia in patients with poor cardiac function or shock:

  • Stroke volume is limited and cardiac output depends on the elevated heart rate 1
  • "Normalizing" the heart rate can cause hemodynamic collapse 1

Recognize that heart rates <150 bpm are unlikely to cause symptoms of instability unless there is impaired ventricular function:

  • At HR 117, symptoms are more likely due to the underlying cause rather than the tachycardia itself 6

Sustained uncontrolled tachycardia can lead to tachycardia-induced cardiomyopathy:

  • After adequate rate control, 25% of patients with ejection fraction <45% show improvement >15% 5
  • Cardiomyopathy generally resolves within 6 months following adequate rate control 5

Monitoring and Follow-up

For patients requiring rate control:

  • Use 24-hour Holter monitoring or exercise testing to evaluate true rate control, rather than relying solely on resting ECG 5
  • During moderate exercise, target heart rate should be 90-115 bpm 5, 6
  • Resting heart rate alone is insufficient to judge adequacy of rate control 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.